Hepion Pharmaceuticals (HEPA) Prices 44.2M Share Common Stock Offering at $2/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St slips as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Bloom Energy shares fall on Oracle project halt
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Hepion Pharmaceuticals Announces Pricing of Public Offering
February 16, 2021 6:45 AM ESTEDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the pricing of its underwritten public offering of 44,200,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $88.4 million before deducting underwriting discounts, commissions and other offering expenses. All of the shares of common stock are being offered by the Company.
ThinkEquity, a division... More
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
February 12, 2021 4:46 PM ESTEDISON, NJ / ACCESSWIRE / February 12, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) ("Hepion Pharmaceuticals" or the "Company") today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company.
ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed,... More
